Tasso
Tasso develops and sells self-administered blood collection devices that enable virtually painless, needle-free sample collection for patients. Its technology supports at-home diagnostic testing and aims to improve patient experience and health by making blood collection more convenient and accessible.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Medical Equipment Manufacturing
- Founded
- 2014
- Type
- Corporation Seattle business license
- Employees
- 99
- Registered name
- Tasso Inc Seattle business license
- Stage
- Series B
- Members see funding amounts. .
- Founders
- Ben Casavant, PhD, Erwin Berthier, PhD
Is this your organization? Claim it
Ben Casavant, PhD, CEO of Tasso, named EY Entrepreneur Of The Year 2026 Mountain West finalist after global growth
Ben Casavant, PhD, co-founder and CEO of Tasso, Inc., was named a finalist for EY US’s Entrepreneur Of The Year 2026 Mountain West award after leading Tasso’s global expansion and development of patient-centric blood collection technologies used in 60+ countries and all 50 U.S. states.
Tasso, Inc. Renews SOC 2 Type 2 Certification Following Independent Audit by Prescient Assurance
Tasso, Inc. announced it renewed its SOC 2 Type 2 certification after an independent audit by Prescient Assurance that produced an unqualified (clean) opinion, reaffirming the company’s commitment to protecting patient and client data across its API and online platforms.
Tasso, Inc. and InnoVero to Provide Athlete-Centric Anti-Doping Blood Collection for 2026 Olympic Winter Games
Tasso, Inc. and InnoVero will supply athlete-centric, secure and minimally painful blood collection technology for anti-doping testing at the 2026 Olympic Winter Games, continuing their partnership after Beijing 2022. The collaboration aims to make sample collection more convenient for athletes while maintaining rigorous, secure testing for clean sport.
Neurogen Biomarking partners with Tasso to use needle-free blood collection for home-based Alzheimer’s testing
Neurogen Biomarking will integrate Tasso’s virtually painless, needle-free blood collection devices into its home-based Alzheimer’s testing service, pairing blood-based biomarker tests with digital cognitive assessments, in-home collection, lab processing, and telehealth review by neurologists.
Tasso, Inc. Reaches Two Million Devices Sold, Expanding Patient Reach Worldwide
Tasso reached a milestone of two million devices sold, expanding its reach to more patients globally and highlighting its impact in an accompanying infographic.
Tasso, Inc. obtains Health Canada license and EU approvals to sell Tasso Mini in Canada, Italy, and Spain
Tasso, Inc. received Health Canada licensing and additional EU approvals allowing its Tasso Mini blood collection device to be sold in Canada, Italy, and Spain, expanding availability beyond its existing U.S. FDA 510(k) clearance and CE Marking. The Tasso Mini is designed for gentle, virtually painless sampling for sensitive or repeat-use patients and now matches the international availability of Tasso’s flagship Tasso+® device.
Tasso, Inc. renews SOC 2 Type II certification with unqualified opinion after Prescient Assurance audit
Tasso, Inc. renewed its SOC 2 Type II compliance certification with an unqualified (clean) opinion after an independent audit by Prescient Assurance, affirming its enterprise-level data security across platforms and APIs. The renewal underscores Tasso’s commitment to protecting sensitive patient data for its patient-centric blood collection solutions.
Lindus Health adopts Tasso’s at-home clinical-grade blood collection to streamline trials and cut costs
Lindus Health will offer Tasso’s painless, at-home clinical-grade blood collection devices as an option in its clinical trials to reduce patient burden, lower costs, and improve recruitment and retention by eliminating or reducing in-person phlebotomy visits.
Tasso Ships One Millionth At‑Home Diagnostic Device, CEO Ben Casavant Celebrates Milestone
Tasso shipped its one millionth at-home diagnostic device, marking a milestone toward making healthcare more accessible and enabling patients to access trials and testing they previously couldn’t. CEO Ben Casavant and the team thank employees, partners, investors, and patients and say they’re focused on continuing growth toward the next million.
Tasso Launches Tasso Care® for Prescreening to Streamline At‑Home Clinical Trial Screening
Tasso launched Tasso Care® for Prescreening, a full-service, at-home blood collection and analysis platform that streamlines clinical trial prescreening to boost enrollment, diversity, and sample quality while expanding panels for multiple therapeutic areas.
Tasso Announces 2023 Growth, CE Mark for Tasso+® and Expanded Commercial, Clinical Partnerships
Tasso reported strong 2023 growth driven by expanding patient-centric, remote blood collection solutions and new commercial, clinical, and community collaborations. The company highlighted milestones such as CE Mark certification for the Tasso+® device and plans to further expand decentralized clinical trial and diagnostic capabilities in 2024.
Tasso, Inc. completes SOC 2 Type 2 audit with no exceptions, validating secure management of patient data
Tasso, Inc. completed a SOC 2 Type 2 audit with no exceptions across all five Trust Services Criteria, confirming its ability to securely manage patient and client data and reinforcing its commitment to privacy and security.
Tasso, Inc. appoints Monica Williams as Chief Financial Officer to accelerate growth
Tasso, Inc. appointed Monica Williams as CFO to support rapid growth of its patient-centric remote blood collection device business, with Williams bringing over 20 years of finance leadership at high-growth tech companies.
Tasso announces CE Mark for Tasso+™ lancet, achieving EU market access and joining prior U.S. 510(k) clearance
Tasso announced CE Mark certification for its Tasso+™ virtually pain-free whole blood collection lancet, enabling sales across the EU and marking full clearance after prior FDA 510(k) Class II clearance; the device aims to expand decentralized clinical trials, home diagnostics, and remote testing access in Europe.
Artyc PBC launches Medstow Mini, a battery-powered reusable cooler for temperature-stable at-home blood sample transport with Tasso collaboration
Artyc PBC launched the Medstow Mini, a reusable battery-powered cooling container that stabilizes and monitors temperature for at-home and clinical blood sample transport, developed with Tasso Inc. to enable temperature-controlled, compliant decentralized testing while reducing waste and emissions.
Tasso, Inc. grows in 2023 with Aptar, CardioRenal and UBC partnerships and earns MDSAP certification
Tasso, Inc. reports strong 2023 growth driven by new partnerships (Aptar Digital Health, CardioRenal, United BioSource/UBC) and rising demand for its at‑home, patient‑centric blood collection solutions, positioning the company for expanded use in decentralized clinical trials and home diagnostics. The company also earned MDSAP certification, enabling regulatory access to Australia, Canada, the U.S., and facilitating entry into markets like Brazil and Japan.
People
-
Ben Casavant Co-Founder and Chief Executive Officer
-
Ben Casavant Executive Officer, Director, Promoter, Co-founder
-
Erwin Berthier Co-Founder and Chief Technology Officer